期刊
NEUROLOGY
卷 96, 期 18, 页码 E2296-E2312出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000011848
关键词
-
资金
- National Institute on Aging-NIH [K23AG059888, K23AG061253]
- Larry L. Hillblom Foundation [K23AG061253, 2018-A025-FEL]
- Bluefield Project to Cure FTD [U24 AG021886, U01 AG016976]
- Alzheimer's Research UK [U24 AG21886]
- Alzheimer's Society
- Brain Research UK
- Wolfson Foundation
- National Institute for Health Research UCL/H Biomedical Research Centre
- Leonard Wolfson Experimental Neurology Centre Clinical Research Facility
- UK Dementia Research Institute
- UKDRI Ltd
- UK Medical Research Council
- Alzheimer's Research UK
- Medical Research Council Clinician Scientist Fellowship [MR/M008525/1]
- National Institute for Health Research Rare Disease Translational Research Collaboration [BRC149/NS/MH]
- Frontotemporal Dementia Research Studentships in Memory of David Blechner funded through The National Brain Appeal [RCN 290173]
- Alzheimer's Society, UK [AS-JF-19a-004-517]
- DRI Ltd
- Canadian Institutes of Health Research
- Chaire de Recherche sur les Aphasies Primaires Progressives Fondation Famille Lemaire
- Swedish Frontotemporal Dementia Initiative Schorling Foundation
- Swedish Research Council
- JPND Prefrontals [2015-02926, 2018-02754]
- Swedish Alzheimer Foundation
- Swedish Brain Foundation
- Karolinska Institutet Doctoral Fund
- KI StratNeuro
- Swedish Dementia Foundation
- Stockholm County Council ALF/Region Stockholm
- Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (German Research Foundation) [EXC 2145, 390857198]
- Medical Research Council UK GENFI grant [MR/M023664/1]
- Bluefield Project
- National Institute for Health Research
- JPND GENFI-PROX grant [2019-02248]
- European Reference Network for Rare Neurologic Diseases [739510]
- NIHR Cambridge Biomedical Research Centre [BRC-1215-20014]
Plasma neurofilament light chain (NfL) can identify asymptomatic carriers of FTLD-causing mutations at risk of disease progression. Higher baseline NfL levels are associated with worse clinical progression, neuropsychological function, and brain atrophy.
Objective We tested the hypothesis that plasma neurofilament light chain (NfL) identifies asymptomatic carriers of familial frontotemporal lobar degeneration (FTLD)-causing mutations at risk of disease progression. Methods Baseline plasma NfL concentrations were measured with single-molecule array in original (n = 277) and validation (n = 297) cohorts. C9orf72, GRN, and MAPT mutation carriers and noncarriers from the same families were classified by disease severity (asymptomatic, prodromal, and full phenotype) using the CDR Dementia Staging Instrument plus behavior and language domains from the National Alzheimer's Disease Coordinating Center FTLD module (CDR+NACC-FTLD). Linear mixed-effect models related NfL to clinical variables. Results In both cohorts, baseline NfL was higher in asymptomatic mutation carriers who showed phenoconversion or disease progression compared to nonprogressors (original: 11.4 +/- 7 pg/mL vs 6.7 +/- 5 pg/mL, p = 0.002; validation: 14.1 +/- 12 pg/mL vs 8.7 +/- 6 pg/mL, p = 0.035). Plasma NfL discriminated symptomatic from asymptomatic mutation carriers or those with prodromal disease (original cutoff: 13.6 pg/mL, 87.5% sensitivity, 82.7% specificity; validation cutoff: 19.8 pg/mL, 87.4% sensitivity, 84.3% specificity). Higher baseline NfL correlated with worse longitudinal CDR+NACC-FTLD sum of boxes scores, neuropsychological function, and atrophy, regardless of genotype or disease severity, including asymptomatic mutation carriers. Conclusions Plasma NfL identifies asymptomatic carriers of FTLD-causing mutations at short-term risk of disease progression and is a potential tool to select participants for prevention clinical trials. Classification of Evidence This study provides Class I evidence that in carriers of FTLD-causing mutations, elevation of plasma NfL predicts short-term risk of clinical progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据